MDACC Study No:2008-0416 ( NCT No: NCT00960752)
Title:Activation of pDCs at the Tumor and Vaccine Site with a TLR Agonist
Principal Investigator:Richard Royal
Treatment Agent:gp100 peptide; MAGE-3; R848 Resiquimod (gel)
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if the vaccines,
gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848),
can help to stimulate the immune system against melanoma.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase II
Treatment Agents:gp100 peptide
R848 Resiquimod (gel)
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Every week for 8 weeks then every 4 weeks for 16 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Richard Royal
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults